WESTON, Fla., Oct. 14, 2019 /PRNewswire/ -- ZyVersa
Therapeutics, Inc., (ZyVersa) a clinical stage specialty
biopharmaceutical company developing first-in-class drugs for
treatment of inflammatory and renal diseases, is pleased to
announce that the October 3rd edition
of BIOCENTURY Innovations reported ZyVersa's viewpoint on
the mounting interest in renal drug development among investors,
biotechs, and pharma. The article, Kidney is the new liver: why
kidney indications are coming into sharp focus, notes that
people are calling the kidney the new liver due to the significant
number of relatively common kidney diseases that have substantial
unmet medical needs resulting in a high economic burden. Within the
past 5 years, renal drug development has been de-risked due to
FDA's acceptance of short-term surrogate endpoints, such as
proteinuria, and the ability to segment patients into homogeneous
groups through AI and machine learning from large patient data
bases, such as Neptune. This has resulted in a surge of interest
and investment in this area, as was seen in the past with liver
disease.
The article mentions that ZyVersa is taking a unique approach to
kidney disease with our lead candidate, VAR 200. VAR 200 targets
podocyte cholesterol accumulation resulting from impaired transport
out of the cells (impaired efflux). The excess cholesterol causes
structural damage to the kidneys' filtration system, resulting in
kidney dysfunction. No other company is pursuing this target. Other
drugs in development are focusing on inflammation, oxidation, and
fibrosis.
A copy of the BIOCENTURY Innovations article can be found
on ZyVersa's website: Click Here.
About VAR 200
VAR 200, 2-Hydroxypropyl-Beta-Cyclodextrin, is a cholesterol
efflux mediator in development for patients with focal segmental
glomerulosclerosis (FSGS), a rare kidney disease. Phase 2a trials
are expected to begin before years' end.
VAR 200 uniquely targets an underlying pathology of kidney
disease, impaired cholesterol removal from the kidneys' filtration
system. The resulting cholesterol accumulation causes structural
damage and kidney dysfunction. There is evidence that VAR 200
promotes cholesterol removal from kidney cells in two different
ways. It has a hydrophobic core that entraps and passively removes
cholesterol from the cells, and it induces active cholesterol
removal by promoting a beneficial change in cholesterol efflux
transporters. As a cholesterol efflux mediator, VAR 200 offers
potential for indication expansion across multiple kidney diseases,
including Alport syndrome and diabetic kidney disease.
About IC 100
IC 100 is a monoclonal antibody that uniquely inhibits the
adaptor ASC component of multiple types of inflammasomes. Because
pathogenesis of numerous chronic inflammatory diseases involves
activation of more than one type of inflammasome (e.g. the NLRP3
inflammasome), IC 100 may be more effective for treating a broad
range of inflammatory diseases than targeting just one. We are
exploring use of IC 100 in two chronic kidney diseases, lupus
nephritis and diabetic kidney disease, among other indications.
By inhibiting ASC, IC 100 blocks inflammasome formation, with
potential to block initiation of the inflammatory cascade. By
inhibiting the ASC component of ASC Specks, IC 100 disrupts the
structure and function of ASC Specks, with potential to block
perpetuation of the inflammatory response responsible for chronic,
damaging inflammation. For more information about IC 100's
mechanism of action, please review the infographic by Clicking
Here.
About ZyVersa Therapeutics, Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company
leveraging advanced, proprietary technologies to develop
first-in-class drugs. Our focus is on patients with inflammatory or
renal diseases who have significant unmet medical needs. Our
clinical pipeline includes a phase 2a-ready asset, VAR 200, a
cholesterol efflux mediator for treatment of a rare kidney disease,
focal segmental glomerulosclerosis (FSGS), and a novel inflammasome
inhibitor with potential to treat multiple inflammatory diseases.
For more information, please visit www.zyversa.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zyversa-therapeutics-viewpoint-on-why-kidney-indications-are-coming-into-sharp-focus-reported-in-biocentury-innovations-article-300937428.html
SOURCE ZyVersa Therapeutics, Inc.